Two recent analyses provide new insight into the clinical efficacy of BCG versus chemotherapy with mitomycin C in intermediate-risk and high-risk bladder cancer. BCG immunotherapy showed a ...

High-risk, non-muscle-invasive bladder cancer is defined as any transitional ... been shown to be superior to monthly maintenance with mitomycin C, the induction of cytokines with a single dose ...

UroGen Pharma's potential remains strong despite market volatility, with promising FDA prospects for UGN-102 & a $5B ...

At AUA 2025, experts will present on novel bladder cancer therapies, advanced renal cell carcinoma comparisons, frailty in ...

UroGen Pharma dosed the first patient for the Phase III UTOPIA clinical trial for UGN-103 (mitomycin) for an intravesical solution to treat low-grade intermediate-risk non-muscle invasive bladder ...

The high recurrence rate and the unpredictability of the progression pattern of bladder cancer have led to the widespread use of intravesical therapy as a supplement to TUR. Superficial bladder ...

She received local radiation therapy, as well as chemotherapy with fluorouracil and mitomycin C ... and a new 1.5-cm tumor on the left lateral bladder wall. Results of an analysis of a urine ...